AZ's Dapagliflozin Impresses In Topline Phase III Heart Failure Study

 
• By John Davis

AstraZeneca’s SGLT2 inhibitor has grabbed attention for its potential role in chronic heart failure patients, with or without type 2 diabetes, following initial results from the DAPA-HF study.  

Digital_Hearts
• Source: Shutterstock

More from Clinical Trials

More from R&D